查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858231

α-甘露甘露醣储积症市场按治疗方法、适应症和最终用户划分 - 全球预测 2025-2032

Alpha Mannosidosis Market by Therapy Type, Indication Type, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，α-甘露醣储积症市场规模将达到 13.0964 亿美元，复合年增长率为 16.86%。

关键市场统计数据
基准年 2024 3.7635亿美元
预计年份：2025年 4.3299亿美元
预测年份 2032 13.0964亿美元
复合年增长率 (%) 16.86%

简明扼要的临床和诊断框架，概述了α-甘露醣储积症缺乏症的病理生理学、其多样化的表型以及当代多学科治疗方法。

α-甘露甘露醣储积症缺乏症是一种罕见的溶小体储积症，由α-甘露糖苷酶缺乏所引起，导致寡糖进行进行性累积并引发多重系统性疾病。临床表现多样，包括发育迟缓、智能障碍、免疫功能障碍、听力丧失、骨骼异常和神经退化等。病情严重程度因表型而异，部分病例在幼儿期进展迅速，而另一些病例则表现为症状较轻、发病较晚。早期诊断和多学科综合管理对于改善预后至关重要，但目前许多患者仍迫切需要能够改变缓解疾病进程的根治性治疗方法。

随着生化和分子遗传学检测技术的进步以及临床医生认识的提高，诊断途径不断发展，使得专科中心能够更早发现疾病。同时，治疗策略也不断发展，造血干细胞移植，尤其是在早期进行时，已成为一种缓解疾病介入手段；酵素替代疗法也逐渐成为治疗全身性酵素缺乏症的标靶治疗。重要的是，管理这种疾病的复杂病程需要整合神经科、听力科、整形外科和心理社会的专业知识，以指导临床决策和长期照护。

随着情况不断演变，临床护理、研究和政策领域的相关人员日益关注优化诊断演算法、加速治疗创新以及确保公平获得新治疗方法。本导言为后续章节奠定了基础，这些章节检验变革性变化、政策层面的阻力、特定领域的影响、区域趋势、企业活动以及针对行业领导者和临床医生的建议行动。

科学突破、监管灵活性和综合医疗服务正在重塑α-甘露甘露醣储积症的治疗研发路径和取得途径。

近年来，科学、监管和给药系统的发展趋势显着改变了α-甘露甘露醣储积症症的治疗模式。在科学方面，精准诊断技术缩短了基因确诊时间，并扩大了对轻症表型的识别范围，重塑了患者识别策略和治疗资格标准。生化生产和生物製药稳定性的进步改善了全身性酵素疗法的製剂选择。同时，基于基因的方法和载体优化的临床前进展正为新的转化研究铺平道路。这些技术进步，加上更完善的自然病史资料和病患报告结局指标，正在改善临床试验设计和终点选择。

法规环境也积极回应罕见疾病的需求，例如采用更灵活的临床试验路径、有条件核准以及加强申办者与监管机构之间的沟通。支付方框架也在不断演变，强调以结果为导向的合约模式以及高成本治疗方法的多方相关利益者分担机制。服务提供方式也在改变。专科医疗中心和综合医疗网络正在整合知识，从而实现早期疗育和更协调的后续追踪。专业的诊断实验室也正在与临床医生合作，以简化检测和转诊流程。

这些变化正在建立一个能够快速将科学发现转化为临床方案的生态系统，同时也推动了生产能力、报销策略和患者准入计划方面更紧密的协调。结果是，α-甘露醣储积症缺乏症治疗药物的研发和交付环境变得更加动态和复杂。

评估2025年海关环境及保护罕见疾病生物製药供应链、临床项目及病患取得途径的切实可行的缓解措施

影响跨境贸易和药品进口的政策变更将于2025年生效，这些变更为生物製药供应链、临床试验物流和存取规划带来了新的变数。关税调整及相关海关措施可能会增加进口治疗药物和原材料的到岸成本，尤其是依赖国际生产网络的特殊生物製药。对于α-甘露醣储积症，由于其供应链通常涉及重组酶、病毒载体和特殊组分等复杂环节，即使进口成本的小幅上涨也可能影响筹资策略、价格谈判以及向专业机构小批量供应药物的可行性。

除了直接的成本影响外，关税造成的供应中断还可能延长关键原材料和成品药物的前置作业时间，从而在临床供应和商业化过程中造成潜在的瓶颈。申办者和服务供应商可能面临与海关合规、分类争议和更严格的文件要求相关的额外行政负担。这些营运上的摩擦可能会使註册研究和核准后研究的时间安排更加复杂，尤其对于患者群体有限且依赖可预测供应週期的罕见疾病项目而言更是如此。

为此，相关人员正采取措施降低关税带来的波动风险。可采取的措施包括：实现供应来源多元化、将部分生产流程迁回国内或地域多角化，以及加强与供应商的合约保护。支付方和医疗系统可以探索区域采购管道，并推动采购机制以稳定供应。此外，与政策制定者和海关当局进行积极对话，有助于明确先进生物製药的分类，并为关键疗法提供临时性救济措施。尤其重要的是，患者权益倡导组织和临床网络在传达临床紧迫性以及促进优先考虑医疗服务连续性的政策对话方面发挥建设性作用。

虽然关税只是影响罕见疾病治疗取得途径​​的众多因素之一，但它们在 2025 年的累积影响凸显了整合供应链风险管理、敏捷製造策略以及相关人员之间协调行动的必要性，以确保受影响的患者能够及时获得治疗。

利用以细分为主导的洞察，将治疗方法、表型变异和医疗保健基础设施联繫起来，从而优化临床开发和准入策略。

我们的細項分析揭示了不同治疗方法、疾病表型和医疗环境带来的差异性影响，有助于指导研发和部署策略。我们基于治疗方法类型研究了骨髓移植和酵素替代疗法市场，这种区分会产生营运方面的影响。造血干细胞疗法需要移植基础设施、供体匹配和长期免疫监测，而酵素替代疗法则需要可靠的低温运输物流、稳定的输注能力和系统化的配送策略。这些不同的运作模式会影响临床中心的选择、病患的出行负担以及专科医疗中心和当地医疗机构之间的协调需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大α-甘露糖苷酶缺乏症的酵素替代疗法产品线
  • 加大对基因疗法的投资，以实现永续的治疗方法
  • 更加重视新生儿筛检措施，以便早期诊断
  • 生技公司与学术机构建立策略伙伴关係，加速α-甘露醣储积症缺乏症的研究
  • 影响患者获得α-甘露醣储积症缺乏症治疗的卫生经济学和报销框架

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依治疗方法的α-甘露醣储积症市场

  • 骨髓移植
  • 酵素替代疗法

9. 依适应症类型分類的α-甘露醣储积症症市场

  • 一型
  • II 型
  • III型

第十章 依最终用户分類的α-甘露醣储积症市场

  • 医院
  • 专科诊所

11. 各地区α-甘露醣储积症市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 α-甘露醣储积症市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

13. 各国α-甘露醣储积症市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abeona Therapeutics Inc.
    • Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
    • Amicus Therapeutics, Inc.
    • BioMarin Pharmaceutical Inc.
    • CHIESI Farmaceutici SpA
    • Eli Lilly and Company
    • JCR Pharmaceuticals Co., Ltd.
    • Kamada Ltd.
    • Orchard Therapeutics PLC
    • Pfizer, Inc.
    • Protalix Biotherapeutics
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Sarepta Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-C002B1C99848

The Alpha Mannosidosis Market is projected to grow by USD 1,309.64 million at a CAGR of 16.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 376.35 million
Estimated Year [2025] USD 432.99 million
Forecast Year [2032] USD 1,309.64 million
CAGR (%) 16.86%

Concise clinical and diagnostic framing of alpha mannosidosis that outlines pathophysiology, varied phenotypes, and contemporary multidisciplinary care approaches

Alpha mannosidosis is a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-mannosidase, leading to progressive accumulation of oligosaccharides and multisystem disease. Clinical manifestations span from developmental delay and intellectual disability to immune dysfunction, hearing loss, skeletal abnormalities, and neurodegeneration. Disease severity varies across phenotypes, with some patients experiencing early childhood decline and others presenting with attenuated, later-onset courses. Early diagnosis and multidisciplinary management are central to improving outcomes, while definitive disease-modifying approaches remain an urgent unmet need for many patients.

Diagnostic pathways have evolved with advances in biochemical assays, molecular genetic testing, and improved clinician awareness, enabling earlier identification in specialist centers. Concurrently, therapeutic strategies are advancing: hematopoietic stem cell transplantation has been used as a disease-modifying intervention, particularly when performed early, and enzyme replacement therapy has emerged as a targeted approach to address systemic enzyme deficiency. Importantly, both clinical decision-making and long-term care require integration of neurologic, audiologic, orthopedic, and psychosocial expertise to manage the complex trajectory of the disorder.

As the landscape evolves, stakeholders across clinical care, research, and policy are increasingly focused on optimizing diagnostic algorithms, accelerating therapeutic innovation, and ensuring equitable access to emerging interventions. This introduction frames the subsequent sections, which examine transformative shifts, policy-level headwinds, segmentation-specific implications, regional dynamics, company activity, and recommended actions for industry leaders and clinicians.

Evolving scientific breakthroughs, regulatory flexibility, and integrated care delivery are reshaping therapy development pathways and access dynamics for alpha mannosidosis

Recent years have been marked by substantive shifts in the alpha mannosidosis landscape driven by scientific, regulatory, and delivery-system trends. On the scientific front, precision diagnostics have shortened the time to genetic confirmation and expanded recognition of milder phenotypes, which in turn reshapes patient identification strategies and eligibility criteria for interventions. Advances in biochemical manufacturing and biologic stabilization have improved formulation options for systemic enzyme therapies, while preclinical progress in gene-based approaches and vector optimization has opened new translational pathways. These technical advancements are complemented by better natural history data and patient-reported outcome measures, which enhance trial design and end-point selection.

Regulatory environments are adapting to rare-disease imperatives through more flexible trial pathways, conditional approvals, and intensified dialogue between sponsors and regulators. Payer frameworks are likewise evolving, with an emphasis on outcomes-based agreements and multi-stakeholder risk-sharing for high-cost therapies. Service delivery is adapting too: centers of excellence and integrated care networks are consolidating expertise, enabling earlier intervention and more coordinated follow-up, and specialized diagnostic labs are forming partnerships with clinicians to streamline testing and referral.

Taken together, these shifts are creating an ecosystem that supports faster translation of scientific insights into clinical options, while simultaneously heightening the imperative to align manufacturing capacity, reimbursement strategies, and patient access programs. The cumulative effect is a more dynamic, but also more complex, environment for developing and delivering therapies for alpha mannosidosis.

Assessment of the 2025 tariff environment and practical mitigation strategies to safeguard biologic supply chains, clinical programs, and patient access for rare disease therapies

Policy changes influencing cross-border trade and pharmaceutical imports in 2025 have introduced new variables for biologic supply chains, clinical trial logistics, and access planning. Tariff adjustments and related customs measures can elevate landed costs for imported therapeutics and raw materials, particularly for specialized biologics that rely on international manufacturing networks. For alpha mannosidosis therapies, which often entail complex supply chains for recombinant enzymes, viral vectors, or specialized components, even modest increases in import costs can affect procurement strategies, pricing negotiations, and the feasibility of small-batch distribution to specialized centers.

Beyond direct cost impacts, tariff-driven disruptions can extend lead times for critical inputs and finished therapies, creating potential bottlenecks for clinical supply and commercialization. Sponsors and service providers may encounter increased administrative burden associated with customs compliance, classification disputes, and the need for enhanced documentation. These operational frictions can complicate the timing of registrational and post-approval studies, particularly for rare-disease programs with limited patient pools that depend on predictable supply windows.

In response, stakeholders are pursuing mitigation strategies that reduce exposure to tariff-induced volatility. Options include diversifying supply sources, reshoring or regionalizing certain manufacturing steps, and strengthening contractual protections with suppliers. Payers and health systems may explore localized procurement channels or advance-purchase mechanisms to stabilize supply. Additionally, proactive engagement with policymakers and customs authorities can clarify classification for advanced biologic products and support temporary relief measures for critical therapies. Importantly, patient advocacy groups and clinical networks play a constructive role in communicating the clinical urgency and facilitating policy dialogues that prioritize continuity of care.

While tariffs are only one factor among many affecting access to therapies for rare diseases, their cumulative impact in 2025 underscores the need for integrated supply chain risk management, agile manufacturing strategies, and coordinated stakeholder action to preserve timely access for affected patients.

Segmentation-driven intelligence linking therapy modality, phenotype heterogeneity, and care-setting infrastructure to refine clinical development and access strategies

Segmentation analysis reveals differentiated implications across therapeutic modality, disease phenotype, and care setting that should inform development and deployment strategies. Based on Therapy Type, market is studied across Bone Marrow Transplantation and Enzyme Replacement Therapy, and this distinction has operational consequences: hematopoietic stem cell-based approaches require transplant infrastructure, donor matching, and long-term immunologic monitoring, while enzyme replacement necessitates reliable cold-chain logistics, regular infusion capacity, and systemic distribution strategies. These divergent operational footprints influence clinical site selection, patient travel burdens, and coordination needs between specialty centers and community providers.

Based on Indication Type, market is studied across Type I Alpha Mannosidosis, Type II Alpha Mannosidosis, and Type III Alpha Mannosidosis, which correspond to a spectrum of severity and progression rates. The differing natural histories across these phenotypes shape therapeutic prioritization and trial enrollment strategies, with early-onset forms often targeted for curative intent interventions and attenuated forms considered for symptom-stabilizing or function-preserving therapies. Clinical outcome measures, caregiver burden assessments, and long-term follow-up protocols must therefore be tailored to phenotype-specific trajectories to capture meaningful benefit.

Based on End-User, market is studied across Hospitals and Specialty Clinics, and this segmentation highlights the importance of aligning distribution and service models to care settings. Hospitals with transplant centers are critical for cell-based interventions and complex perioperative care, whereas specialty clinics and infusion centers provide longitudinal management, monitoring, and routine administration for enzyme therapies. Transition-of-care procedures between these settings are essential, especially for pediatric-to-adult handoffs and for maintaining adherence to long-term treatment regimens. Overall, segmentation underscores the need for differentiated commercial strategies, clinical-support infrastructures, and patient engagement models that match therapy modality, disease phenotype, and the realities of where care is delivered.

Comparative regional analysis showing how diagnostics, regulatory diversity, and health system capacity shape access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics significantly influence clinical development pathways, regulatory engagement, and access strategies, and recognizing geographic variation is critical for effective program planning. In the Americas, a concentration of specialized treatment centers, established transplantation programs, and strong rare-disease advocacy networks facilitates patient identification and trial enrollment, while regulatory agencies increasingly offer dedicated pathways for expedited review of transformative therapies. This environment supports early adoption of novel interventions but also requires sophisticated reimbursement strategies and stakeholder alignment to navigate pricing and access discussions.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse healthcare financing models create both opportunities and complexities. Several European jurisdictions have adaptive frameworks for orphan medicinal products and are active in outcomes-based contracting, but variability in diagnostic capacity and treatment infrastructure across countries necessitates nuanced regional approaches. Stakeholders must invest in local evidence generation, stakeholder education, and partnerships with clinical centers of excellence to ensure equitable access across varied healthcare systems.

In the Asia-Pacific region, rapid expansion of molecular diagnostic capacity and growing clinical trial activity are enabling broader identification of patients and participation in global development programs. However, disparities in reimbursement mechanisms and infrastructure mean that access pathways differ markedly between urban tertiary centers and more resource-limited settings. Strategic collaborations with regional manufacturing partners, investment in cold-chain logistics, and engagement with national health authorities are effective levers to support introduction and sustainable delivery of advanced therapies across the region.

Across all regions, coordinated engagement with patient organizations, investment in diagnostic networks, and alignment of supply-chain strategies are essential to translate clinical advances into meaningful patient outcomes. Tailoring regulatory and commercial approaches to regional realities improves the probability of timely and equitable access to new interventions.

Industry activity in alpha mannosidosis reflects a mix of established biologic developers, clinical-stage innovators, and specialized service providers collaborating to advance therapeutic options and care delivery. Established players bring manufacturing scale, regulatory experience, and commercial infrastructure that are valuable for late-stage development and post-approval supply stability. Smaller clinical-stage companies and academic consortia contribute innovation in gene-based modalities, vector engineering, and novel delivery mechanisms that target central nervous system manifestations and aim to improve durability of response.

Partnership models are prominent, often coupling translational expertise from academic centers with industry capabilities in manufacturing and regulatory strategy. These alliances accelerate the translation of preclinical findings into first-in-human studies and support complex trial designs that incorporate natural history comparators and adaptive elements. Concurrently, specialized contract development and manufacturing organizations are expanding capacity for viral vectors, recombinant enzymes, and cell therapy components, addressing a critical bottleneck for scalability and supply reliability.

Beyond product development, companies are investing in patient support ecosystems that include genomic testing partnerships, educational initiatives for clinicians, and long-term outcome registries. These capabilities are increasingly recognized as essential for rare-disease programs, both to support evidence generation and to enable coordinated care. Collectively, the company landscape demonstrates a pragmatic blend of deep scientific investment, collaborative partnerships, and operational scaling to meet the unique demands of developing and delivering therapies for alpha mannosidosis.

Actionable cross-functional strategic priorities that align diagnostics, resilient supply chains, payer engagement, and patient support to accelerate therapy adoption and access

Leaders in industry and clinical practice should prioritize integrated strategies that align science, supply, and access to reduce time-to-patient impact for alpha mannosidosis. First, invest early in robust diagnostic and natural history data collection to de-risk development pathways and to define clinically meaningful endpoints that resonate with regulators and payers. Second, build resilient supply architectures by diversifying manufacturing footprints, securing critical raw materials, and exploring regional manufacturing partnerships to mitigate cross-border friction and tariff-related risks.

Third, engage payers and health-system stakeholders proactively to design value-based access models that reflect long-term clinical benefits and address affordability concerns. This includes developing post-authorization evidence-generation plans and pragmatic outcome measures to support performance-based agreements. Fourth, cultivate strategic alliances with transplant centers, specialty clinics, and patient organizations to establish referral networks, streamline care pathways, and optimize patient enrollment in clinical programs. Fifth, prioritize patient and caregiver support programs that address psychosocial, logistical, and adherence barriers, thereby enhancing real-world outcomes and long-term follow-up completeness.

Finally, maintain ongoing policy engagement with regulators and customs authorities to clarify classification and facilitate preferential handling of critical biologics. By integrating these actions into a coordinated strategy, stakeholders can improve the probability of successful development, sustainable supply, and equitable access for patients living with alpha mannosidosis.

Transparent mixed-methods research approach combining expert interviews, literature synthesis, regulatory analysis, and supply-chain evaluation to ensure practical and validated findings

This research synthesis is grounded in a mixed-methods approach that integrates primary stakeholder interviews, peer-reviewed literature, regulatory filings, clinical trial registries, and operational assessments of supply-chain resilience. Primary inputs included structured interviews with clinicians, program leads at treatment centers, manufacturing and logistics experts, and patient-advocacy representatives to capture real-world perspectives on diagnosis, care delivery, and access barriers. Secondary research encompassed current scientific literature on alpha mannosidosis pathophysiology, clinical management, and therapeutic approaches, as well as public regulatory guidance and policy pronouncements relevant to rare-disease development.

Where feasible, clinical trial registries and public company disclosures were analyzed to understand development trajectories, trial designs, and evidence-generation strategies without relying on proprietary commercial datasets. Supply-chain assessments drew on industry-accepted frameworks for biologic manufacturing and distribution to evaluate vulnerability points and mitigation tactics. Throughout the research process, findings were triangulated across multiple sources to ensure internal consistency, and draft conclusions were validated via follow-up discussions with subject-matter experts to refine practical implications.

This methodology balances depth and rigor while protecting patient privacy and adhering to ethical standards for research. The resulting analysis aims to be actionable for stakeholders involved in clinical development, manufacturing, policy, and care delivery.

Integrated outlook that synthesizes clinical promise with operational and policy imperatives to translate therapeutic innovation into sustained patient benefit

Alpha mannosidosis presents both pressing clinical challenges and tangible opportunities for therapeutic innovation and system-level improvement. Scientific advances in diagnostics, enzyme therapies, and gene-based approaches have brought renewed momentum to the field, while adaptive regulatory mechanisms and evolving payer models offer pathways to translate clinical benefit into patient access. At the same time, operational realities-ranging from the need for coordinated multidisciplinary care to supply-chain vulnerabilities accentuated by policy shifts-require deliberate, cross-stakeholder strategies.

Moving forward, success will depend on integrating robust evidence generation with resilient manufacturing and distribution plans, and on engaging payers, providers, and patient communities early and continuously. Stakeholders who align clinical development with real-world care pathways, invest in durable supply capabilities, and pursue collaborative reimbursement arrangements will be best positioned to deliver sustained patient benefit. In short, the trajectory for alpha mannosidosis is promising, but realizing its potential will require coordinated action across science, operations, and policy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of enzyme replacement therapy pipelines targeting alpha mannosidase deficiency
  • 5.2. Growing investment in gene therapy approaches for sustainable alpha mannosidosis treatment
  • 5.3. Rising focus on newborn screening initiatives to enable early alpha mannosidosis diagnosis
  • 5.4. Strategic partnerships between biotech companies and academic centers accelerating alpha mannosidosis research
  • 5.5. Health economics and reimbursement framework influencing patient access to alpha mannosidosis therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alpha Mannosidosis Market, by Therapy Type

  • 8.1. Bone Marrow Transplantation
  • 8.2. Enzyme Replacement Therapy

9. Alpha Mannosidosis Market, by Indication Type

  • 9.1. Type I Alpha Mannosidosis
  • 9.2. Type II Alpha Mannosidosis
  • 9.3. Type III Alpha Mannosidosis

10. Alpha Mannosidosis Market, by End-User

  • 10.1. Hospitals
  • 10.2. Specialty Clinics

11. Alpha Mannosidosis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Alpha Mannosidosis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Alpha Mannosidosis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abeona Therapeutics Inc.
    • 14.3.2. Alexion Pharmaceuticals, Inc. by AstraZeneca PLC
    • 14.3.3. Amicus Therapeutics, Inc.
    • 14.3.4. BioMarin Pharmaceutical Inc.
    • 14.3.5. CHIESI Farmaceutici S.p.A.
    • 14.3.6. Eli Lilly and Company
    • 14.3.7. JCR Pharmaceuticals Co., Ltd.
    • 14.3.8. Kamada Ltd.
    • 14.3.9. Orchard Therapeutics PLC
    • 14.3.10. Pfizer, Inc.
    • 14.3.11. Protalix Biotherapeutics
    • 14.3.12. Quest Diagnostics Incorporated
    • 14.3.13. Sanofi S.A.
    • 14.3.14. Sarepta Therapeutics, Inc.
    • 14.3.15. Takeda Pharmaceutical Company Limited
    • 14.3.16. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALPHA MANNOSIDOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE I ALPHA MANNOSIDOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE II ALPHA MANNOSIDOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY TYPE III ALPHA MANNOSIDOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 57. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 59. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 68. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 70. NORTH AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 78. LATIN AMERICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 87. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 94. EUROPE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 102. MIDDLE EAST ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 103. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 110. AFRICA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 128. ASEAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 129. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 136. GCC ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 145. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 152. BRICS ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 153. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 160. G7 ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 161. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 168. NATO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ALPHA MANNOSIDOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 177. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. MEXICO ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED KINGDOM ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 201. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. GERMANY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. FRANCE ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. RUSSIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 219. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. ITALY ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. SPAIN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. CHINA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. INDIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 243. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. JAPAN ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. AUSTRALIA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY INDICATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 260. SOUTH KOREA ALPHA MANNOSIDOSIS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 261. ALPHA MANNOSIDOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 262. ALPHA MANNOSIDOSIS MARKET, FPNV POSITIONING MATRIX, 2024